Identification of Phenylsulfone-Substituted Quinoxaline (WYE-672) as a Tissue Selective Liver X-receptor (LXR) Agonist

Citations Over TimeTop 10% of 2010 papers

Abstract

A series of phenyl sulfone substituted quinoxaline were prepared and the lead compound 13 (WYE-672) was shown to be a tissue selective LXR Agonist. Compound 13 demonstrated partial agonism for LXRbeta in kidney HEK-293 cells but did not activate Gal4 LXRbeta fusion proteins in huh-7 liver cells. Although 13 showed potent binding affinity to LXRbeta (IC(50) = 53 nM), it had little binding affinity for LXRalpha (IC(50) > 1.0 microM) and did not recruit any coactivator/corepressor peptides in the LXRalpha multiplex assay. However, compound 13 showed good agonism in THP-1 cells with respect to increasing ABCA1 gene expression and good potency on cholesterol efflux in THP-1 foam cells. In an eight-week lesion study in LDLR -/- mice, compound 13 showed reduction of aortic arch lesion progression and no plasma or hepatic triglyceride increase. These results suggest quinoxaline 13 may have an improved biological profile for potential use as a therapeutic agent.

Related Papers

• → Novel Roles of Liver X Receptors Exposed by Gene Expression Profiling in Liver and Adipose Tissue(2002)160 cited
• → Identification of human low‐density lipoprotein receptor as a novel target gene regulated by liver X receptor alpha(2006)46 cited
• → Discovery and optimization of a series of liver X receptor antagonists(2012)19 cited
• Liver X receptor agonists dampen NLRP3 inflammasome activation(2014)
• Effect of LXR agonist hyodeoxycholic acid dimethyl amide on vertebrate behavior(2010)